Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00170521
Other study ID # 05-0018
Secondary ID Leon GrAS2000
Status Terminated
Phase N/A
First received September 12, 2005
Last updated August 26, 2010
Start date August 2006
Est. completion date August 2008

Study information

Verified date December 2006
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine the epidemiology of throat isolates of group A streptococci among 3-15 year-old children with pharyngitis (sore throat) living in Leon, Nicaragua.


Description:

Streptococcus pyogenes (GrAS) is a human pathogen that leads to great disease burden throughout the world. In the United States, an estimated 30 million infections occur yearly. Most of these are local infections of the skin or the throat but still lead to considerable use of health-care resources. These common, simple forms of GrAS disease may progress to or be followed by the more serious GrAS-related illnesses acute rheumatic fever, post-streptococcal glomerulonephritis, streptococcal toxic shock syndrome, sepsis, pneumonia, or other invasive illnesses. Outside the U.S., in the developing world, the burden of GrAS-related disease is presumed to be even higher, but is not completely elucidated in many of the poorer regions of the world. It is known, though, that rheumatic heart disease causes more cardiovascular morbidity in the children of the world than any other illness. Although the incidence of rheumatic fever in the U.S. has fallen to levels of approximately 0.5 per 100,000 per year, in some areas, the developing world's children still have rates over 100 per 100,000 per year. The percentage of cardiac admissions attributable to rheumatic heart disease in hospitals located in the developing world remains in the range of 30 to 50%, where it has been studied. GrAS is one of the best characterized human pathogens with regards to its microbiology, its spectrum of diseases, and its ability to lead to serious sequelae such as rheumatic fever and glomerulonephritis. Yet, efforts to control it through the use of antibiotics have been only partially successful in the United States and largely unsuccessful in the developing world. The health impact of uncomplicated streptococcal infections, such as pharyngitis, and the less common but more severe diseases, such as rheumatic heart disease, must be better studied in order to move forward with control measures. In this study, patients aged 3-15 presenting with sore throat, fever and cervical lymphadenopathy will be examined and a throat swab will be submitted to the lab for culture. All of these patients will be treated with either benzathine penicillin or, if they have a history of allergy to penicillin, oral erythromycin. The parent will be given a follow-up appointment to convey the result of the culture and to evaluate the course of the child's illness. Children presenting with sore throat only will be cultured and given a follow-up appointment to return after the result of the culture is known. Antibiotic treatment is given only if the culture is positive for group A streptococci. Within this algorithm is latitude for the physician to treat any patient based on clinical signs and symptoms and the concern that a particular child may not return for treatment if it is delayed based on the culture result. The overriding goal is the prevention of acute rheumatic fever and suppurative complications. The primary objective of this study is to characterize the GrAS isolates genotypically (emm type or sub-type). The secondary objective is to describe the epidemiology of throat isolates of GrAS among 3- to 15- year old children with pharyngitis living in Leon, Nicaragua. Primary endpoint of the study is the frequency and proportion of each emm-type among children with pharyngitis. Secondary Endpoints for the study are as follows: The proportion of children with pharyngitis from whom GrAS is isolated. The minimal incidence of GrAS pharyngitis in children based on annual cases per 100,000 children in the catchment areas. The age, gender, and ethnicity-specific minimal incidence rates of GrAS pharyngitis in children living in the catchment areas.


Recruitment information / eligibility

Status Terminated
Enrollment 13000
Est. completion date August 2008
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 3 Years to 15 Years
Eligibility Inclusion Criteria:

1. All children 3- to 15-years old with pharyngitis who are seen at a participating site will be invited to participate.

Exclusion Criteria:

1. Subjects whose parents are unable or unwilling to provide informed consent will be excluded from the study.

2. Children who are 13 years or older and unable or unwilling to provide informed consent will be excluded form the study.

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Nicaragua National Autonomous University of Nicaragua, Leon Leon

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

Nicaragua, 

See also
  Status Clinical Trial Phase
Completed NCT00307112 - Rheumatic Heart Disease Prevalence in Leon, Nicaragua
Completed NCT00284843 - Prevalence of RHD, Pyoderma and Scabies in Children in Fiji N/A
Completed NCT00284882 - Incidence of Group A Strep Pharyngitis in School Children in Fiji N/A
Completed NCT00436891 - Streptococcal Infections in Fiji - Prevalence of Group A Streptococcal Pyoderma and Scabies in Infants in Fiji N/A
Completed NCT00264771 - Hospital Based Incidence of Group A Streptococcal Disease in Fiji N/A
Completed NCT00264784 - GAS Epi Study to Measure Age-Related Antibody Titers to J8 Vaccine N/A
Completed NCT00305123 - Molecular Epidemiology of Streptococcus Pyogenes Among Children in Bamako, Mali N/A